Search results
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 1 day agoNovavax stock rocketed to a nearly two-year high in June, thanks to a $1.3 billion deal and the...
CDC recommends Novavax COVID vaccine after unanimous vote
CBS News via Yahoo News· 2 years agoA panel of the Centers for Disease Control and Prevention's outside vaccine advisers voted...
Novavax Covid vaccine becomes fourth to receive FDA approval
The Independent via Yahoo News· 2 years agoThe Food and Drug Administration authorised the use of Novavax Covid-19 vaccine for adults on...
Novavax’s COVID-19 vaccine gets the green light from the FDA, giving third option for protection
Salon via Yahoo News· 9 months agoNovavax Vaccine Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images On Tuesday, the...
FDA authorizes Novavax's updated COVID vaccine
CBS News via Yahoo News· 9 months agoThe Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and...
What’s in the Novavax Vaccine? Experts Break It All Down
Prevention via AOL· 2 years agoThe Food and Drug Administration has authorized Novavax’s COVID-19 vaccine for use in the U.S....
Novavax CEO eyes next batch of COVID-19 vaccines after CDC approval
Yahoo Finance· 2 years agoNovavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first...
FDA, CDC greenlight Novavax's original COVID-19 vaccine as booster
Yahoo Finance via AOL· 2 years agoThe FDA and CDC greenlit Novavax's (NVAX) original COVID-19 vaccine for use as a booster in some...
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
Investor's Business Daily· 1 year agoNovavax plans to update its Covid shot for new variants, and NVAX stock outperformed its vaccine...
3 Reasons to Buy Novavax and 1 to Sell
Motley Fool· 2 years agoNovavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying...
